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Clinical research plays a vital role in producing knowledge valuable for 
understanding human disease and improving healthcare quality. Human subject 
protection is an obligation essential to the clinical research endeavor, much of which is 
governed by federal regulations and rules. Institutional Review Boards (IRBs) are 
responsible for overseeing human subject research to protect individuals from harm and 
to preserve their rights. Researchers are required to submit and maintain an IRB 
application, which is an important component in the clinical research process that can 
significantly affect the timeliness and ethical quality of the study. As clinical research has 
expanded in both volume and scope over recent years, IRBs are facing increasing 
challenges in providing efficient and effective oversight. The Clinical Research 
Informatics (CRI) domain has made significant efforts to support various aspects of 
clinical research through developing information systems and standards. However, 
information technology use by IRBs has not received much attention from the CRI 
community.  
This dissertation project analyzed over 100 IRB application systems currently used at 
major academic institutions in the United States. The varieties of system types and lack 
of standardized application forms across institutions are discussed in detail. The need for 






In this dissertation, I developed an IRB domain analysis model with a special focus 
on promoting interoperability among CRI systems to streamline the clinical research 
workflow. The model was evaluated by a comparison with five real-world IRB 
application systems. Finally, a prototype implementation of the model was demonstrated 
by the integration of an electronic IRB system with a health data query system.  
This dissertation project fills a gap in the research of information technology use for 
the IRB oversight domain. Adoption of the IRB domain analysis model has potential to 
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Clinical research is aimed at investigating new approaches to the diagnosis, treatment, 
and prevention of human disease. It plays an important role in improving the quality of 
healthcare. Clinical researchers are faced with increasingly complex workflows through 
the entire study life cycle and critical requirements for efficient management and reuse of 
large amounts of research data and metadata. Significant effort has focused on designing 
biomedical informatics tools that support efficiently conducting and tracking studies. 
These efforts led to the emergence of a domain that has become a subdiscipline of 
biomedical informatics focused on clinical research referred to as Clinical Research 
Informatics (CRI).[1,2] Example CRI systems include but are not limited to Secondary 
Use of Health Data systems (SUHD) (e.g., hospital data warehouses, distributed health 
data repositories, disease registries), Clinical Trial Management Systems (CTMS), 
Electronic Data Capture (EDC) systems (e.g., REDCap,[3] OpenClinica[4]), Clinical 
Trial Registries (CTR) (e.g., ClinicalTrials.gov), and electronic submission and reporting 
systems (e.g., Electronic Submissions Gateway,[5] MedWatch[6]) supported by the Food 
and Drug Administration (FDA). 
Human subject protection is an obligation essential to the clinical research endeavor, 







 and Human Services’ (HHS) Protection of Human Subjects regulations[7]; the Food and 
Drug Administration’s (FDA) human subject protection regulations[8–11]; the Health 
Insurance Portability and Accountability Act (HIPAA) Privacy Rule (also known as 
Standards for Privacy of Individually Identifiable Health Information); and the most 
recent Omnibus Final Rule which is a modification to the HIPAA rules under the Health 
Information Technology for Economic and Clinical Health Act (HITECH) and the 
Genetic Information Nondiscrimination Act (GINA).[12] The federal regulations delegate 
authority to Institutional Review Boards (IRB)
a  
to review and monitor any research 
involving human subjects to protect individuals from harm and preserve their rights. 
IRBs are required to conduct continuing review of research at intervals and to observe the 
consent process when necessary. 
As the volume of research grew in recent years, the number of IRBs in the United 
States also increased substantially. A previous study shows that the number of IRBs has 
increased by 41% from 2004 to 2008.[13] According to the latest data from the OHRP, 
there are 2937 Institutional Review Board Organizations (IORGs), which include 3589 
IRBs actively registered. 
1.1 Problem Analysis 
Clinical research professionals spend a great deal of their time preparing IRB 
applications. After a study is approved and open, amendments, application renewals, and 
unanticipated problems reports must be submitted to the IRB for continued monitoring. 
                                                          
a
 “IRB" is a generic term used by HHS and FDA to refer to a group whose function is to review 
research to assure the protection of the rights and welfare of the human subjects. Each institution 
may use different names such as Research Ethics Committee, Committee on Human Studies, the 
Committee on Clinical Investigations, etc. For the sake of simplicity, this dissertation will use the 








The clinical research landscape has changed dramatically in recent years in terms of both 
volume and complexity. According to the latest data from ClinicalTrials.gov, the number 
of registered studies has increased 66% from 2010 to 2013.[14] Retrospective research 
involving secondary use of patient data has also been greatly encouraged and facilitated 
by the wide adoption of electronic health record (EHR) systems, which will be discussed 
in detail in Chapter 2.  Recent years have seen a growing trend towards multisite clinical 
research, which offers numerous scientific advantages over single-site studies.[15,16] 
This changing nature of clinical research has caused new challenges for both clinical 
researchers and IRB reviewers. The remarkable growth of clinical research has resulted in 
an unprecedented increase in workload for IRBs, especially for large academic research 
institutions.[13] Variations in submission requirements, application formats, application 
questions, and review procedures across different IRBs have posed significant challenges 
specially for multisite studies.[17–19] Studies show that investigators complain that the 
IRB application process is burdensome and, in some instances, waiting to obtain IRB 
approval has delayed project initiation.[13,20–22] These issues are complicated by the 
political, educational and technical aspects of the human subject projection domain. A 
complete solution may include reforms in policies, administrative operational procedures, 
and technology uses. This dissertation focuses on only the technical aspect of the 
potential solution and considers other aspects to be beyond the scope of the dissertation. 
Information technology has been proven to have enormous potential for improving the 
performance of organizations.[23] It has contributed to high productivity in many 








In the human subject protection domain, many institutions are employing some form 
of information technology to support IRB application submissions, tracking, and reviews. 
The term e-IRB will be used to refer to these information systems. According to the 2011 
metrics report from the Association for the Accreditation of Human Research Protection 
Programs, Inc. (AAHRPP), shown in Figure 1, more than 90% of institutions use a 
database to track IRB applications. However, only about half of the institutions use an 
online system for IRB application processing, but the trend has increased from 2009.  
The AAHRPP metrics report gives us a general idea of the information technology 
employment in IORGs. However, the capability of these IRB systems may vary greatly 
across organizations. Some institutions may electronically store only the descriptive 
information of the IRB applications for tracking purposes but not the IRB applications 
themselves. Some institutions may scan IRB applications from hard copies and store 
them as images. Some institutions may accept word or PDF IRB applications via e-mail 
or Flash disk and store them in a document management system like SharePoint.[24] In 
addition to the format varieties, the content and structure of IRB applications are 
specified by each institution and can vary enormously. The IRB application can include 
large sections of free text, or structured data elements that can be interpretable by 
computers. 
Problems with the varieties of format and content of IRB applications across 
institutions are summarized as follows, whereas more detailed analysis will be discussed 









Figure 1. AAHRPP Metrics Report 2011: Technology Use by Organizations with an IRB 
Three-Year Trends 
1. The content of the scanned paper IRB applications or IRB applications stored in word 
or PDF files is hard to search across documents. The IRB application repository is a 
valuable resource for archiving all human subject research conducted at an institution. 
It can be potentially helpful to different stakeholders such as investigators, reviewers, 
policy makers, and accreditation institutions for future analysis, performance 
measurement, reporting, and auditing. Investigators and IRB reviewers may need to 
use previously reviewed studies with similar features as a reference to help design 
and review a current study. For example, a commentary has proposed to organize 
information about incentives offered to participants with reference to a commonly 
recognized set of ethically salient parameters (e.g., condition under study, study 
population, types and levels of risks, research setting, etc.).[25] Currently, there are 
considerable variations in the types and amounts of incentives even for studies with 







images or unstructured documents will limit the ability to search and analyze such 
information across studies efficiently, thus hindering IRBs from developing and 
applying consistent incentive policies from comparable practices.  
2. Free-text content is often ambiguous and lacks clarity in describing the study. This 
will impact the review quality and efficiency. For example, to ensure that study 
information, such as eligibility criteria and planned study procedures, is specified 
clearly and consistently throughout the protocol, IRB reviewers often need to ask for 
clarification from researchers. Free-text application information is hard for computers 
to process in order to assist human review. Alternatively, if the area of study is 
recorded in a more structured format, the application can be automatically assigned to 
IRB members with corresponding experiences and expertise. Depending on whether 
the planned study activities involve high-risk procedures such as ionizing radiation or 
only informational risk such as secondary use of existing data or specimens, 
commensurate review procedures for risk can be suggested by the system. This can 
help IRBs allocate their limited resources to ensure human subject protection while 
enabling responsible research to proceed. 
3. The lack of uniformity of IRB application information impedes system interactions 
with other CRI tools, causing cumbersome workflows for clinical research. There is 
overlapping study information across different CRI systems. Without system 
integration, investigators need to enter duplicate study information into each system. 
For systems requiring IRB approval before certain actions can take place, the 
investigators may need to manually submit the IRB approval letter to different 







forms is one of the causes for inconsistency in ethics review for multisite studies.[26] 
The application format and content variations across different IRBs also make the 
application and review decision information sharing and exchange difficult, impeding 
efficient communication and cooperation among IRBs. 
4. Each IRB expends effort developing local application templates or Web forms even 
though a large part of the content is essentially common across different IRBs in 
order to be compliant with best practices and regulations. 
Despite the increasing interest and effort in developing and harmonizing standards for 
clinical research to share and reuse research data and metadata across projects and across 
institutions in the CRI domain,[27,28] e-IRB systems have not attracted much attention in 
the CRI community. However, IRB application and oversight is an important component 
in the clinical research process and can significantly affect the timeliness and ethical 
quality of the study. 
1.2 Research Objective 
To our knowledge, there is no existing research addressing e-IRB systems in the CRI 
domain. This dissertation aims to fill this research gap by: 
1. Analyzing the IRB application systems used at 61 Clinical and Translational Science 
Award (CTSA) centers to understand the major application system types and gain a 
deeper insight into the diversities of IRB application systems within and across 
institutions. 
2. Developing an IRB domain analysis model (IRB DAM) to support standard, 
implementation-independent, and machine-understandable representation of IRB 







between e-IRB systems and other CRI systems to streamline the clinical research 
process; and b) support a consistent and structured e-IRB design that makes 
automated review decision support possible, thus enhancing the quality and efficiency 
of ethics review. 
3. Evaluating the static aspect of the IRB DAM by mapping five real-world IRB 
application systems with different designs from different institutions to the IRB DAM 
model.  
4. Demonstrating a prototype implementation of the model by integrating an e-IRB 
system with a health data query system for secondary use to support automated access 
control on Protected Health Information (PHI) based on IRB review decisions. 
The dissertation is organized as follows: Chapter 2 describes the original motivation 
of this work and related previous research; Chapters 3, 4, 5, and 6 describe the methods 
and results for each of the aims mentioned above. Chapter 7 discusses the limitations of 











This research project was initially motivated by the need for automated PHI access 
control for the Federated Utah Research and Translational Health e-Repository 
(FURTHeR) project. FURTHeR is hosted in the Center for Clinical and Translational 
Science (CCTS) at the University of Utah and utilizes real-time data model and 
terminology translation services to transform an investigator’s query to query 
representations appropriate for heterogeneous data sources and return federated 
results.[29] The current release of FURTHeR adapted the existing i2b2 (Informatics for 
Integrating Biology and the Bedside)[30] Web client front-end as the query user 
interface, allowing investigators to compose and execute queries and view aggregated, 
federated results.[31] However, to deliver individual-level PHI to investigators, 
appropriate and efficient security mechanisms must be employed to ensure patient 
privacy. This is a common challenge faced by most secondary use of health data systems, 
which will be discussed in further detail in the following subsections. 
2.1.1 Secondary Use of Health Data for Research 
Widespread adoption of information technology such as EHR systems in healthcare 







of such data. Secondary use of health data for research purposes includes but is not
limited to postmarketing safety surveillance of drugs and devices, health services 
research, comparative effectiveness analysis, and identification of potential participants 
for clinical trials.[32–35] Secondary use of health data is one of the most promising ways 
to improve patient care with lower cost and greater timeliness. 
Efforts are increasing towards building informatics tools to support secondary use of 
health data for research purposes. The term SUHD will be used to refer to this type of 
information system.  Many hospitals have established enterprise data warehouses (EDW) 
or disease registries that extract patient data from the operational EHR environment into a 
central repository designed to support research and quality improvement projects. There 
are also cross-institutional and national efforts towards developing informatics 
infrastructures and standards to facilitate access to multiple data sources, including but 
not limited to the cancer Biomedical Informatics Grid (caBIG
®
),[36] i2b2,[37] FURTHeR, 
the Query Health Initiative,[38] and the SHARPn platform developed by the Strategic 
Health IT Advanced Research Projects Area 4 Consortium.[39]  
Some SUHD systems provide a query interface directly accessible to researchers to 
enhance clinical research efficiency. The i2b2 Web client is one of those tools that has 
been popularly adopted or adapted. It allows users to build and run queries that specify 
clinical criteria for a desired cohort by using simple drag-and-drop methods in a Web 
browser client. The Shared Health Research Information Network (SHRINE), for 
example, deployed the i2b2 software suite in a federated environment and can return 
aggregated counts of eligible subjects for preparatory-to-research activities.[40] The 







Institute, also utilizes i2b2 to allow users to directly discover patient cohorts. Patient sets 
can be extracted from queries only with proper IRB approval.[41] The STRIDE (Stanford 
Translational Research Integrated Database Environment) Cohort Discovery Tool (CDT) 
from the Stanford Center for Clinical Informatics allows Stanford researchers to query 
the STRIDE Clinical Data Warehouse (CDW) and returns the approximate number of 
patients matching the search criteria.[42]  No patient identifiers or clinical data, however, 
are revealed before Stanford IRB approval is obtained. The Query Health Initiative led by 
the Office of the National Coordinator for Health Information Technology (ONC) is 
designed based on the principle of “bringing questions to data” instead of the 
conventional approach “bringing data to questions,” in which data sources ultimately 
retain control over the decisions whether to respond to a distributed query as well as 
maintaining control over the data to be released. The current Query Health reference 
implementation supports only  aggregated query results.[43] 
2.1.2 Privacy Concerns 
A secondary use healthcare data repository and a query interface directly accessible to 
researchers provide a more convenient approach for preparatory to research activities. 
However, as demonstrated above, most of the existing query interfaces allow aggregated 
results only for data requests and none of them allow streamlined individual-level data 
access without manually checking for IRB approval due to privacy concerns. 
There are efforts towards de-identification of health data for research purposes since 
de-identified data are not covered by the HIPAA Privacy Rule. However, de-identification 
cannot completely solve privacy issues for the following reasons. First, de-identified data 







researchers may need PHI to recruit participants. Second, there are re-identification risks 
for HIPAA Safe Harbor and Limited Dataset policies. It is difficult to fully de-identify 
health data. Third, even though de-identified data are not regulated under the HIPAA 
Privacy Rule, there are local or institutional policies for accessing de-identified data, 
which usually require reviews from IRBs, although this could be an exempt or expedited 
review instead of a full review. 
Therefore, one of the major concerns raised by these SUHD systems is how to handle 
data requests from researchers and deliver the desired data set accurately and efficiently 
without compromising patient privacy. While maintaining privacy and confidentiality is 
essential to ethical research, insufficient oversight procedures can also hinder progress in 
biomedical research and create cumbersome research processes. Problem with the current 
IRB oversight of SUHD studies were illustrated in detail in our previously published 
paper,[44] from the point of view of the investigator, the data provider, and the IRB.  
Although there are discussions in the advance notice of proposed rulemaking released 
by HHS about whether data-only research projects posing  informational risks (e.g., 
resulting from the unauthorized release of information about subjects) should be 
reviewed by IRBs,[45] this is considered as a regulatory issue that is outside the scope of 
this research project. Our goal is to employ information technology to streamline the 
research process while staying compliant with current regulations. 
2.1.3 Automated Access Control of PHI Based on IRB Approval 
The inefficient and time-consuming process for accessing PHI is caused by the 
information disconnect between SUHD systems and e-IRB systems. In a previous paper, 







system, ERICA, to achieve automated access control on PHI based on IRB approval.[44] 
The integrated framework aims to streamline the current data request and access 
workflow for researchers, IRBs, and data custodians. The data elements requested by an 
investigator and associated IRB review decisions will be shared between the two systems 
in a meaningful way so that the IRB knows what data elements are requested by the 
investigator and the data query system knows what data elements are approved by the 
IRB for an investigator to access. 
2.2 Why a Model Is Needed 
To enable meaningful information exchange between FURTHeR and ERICA as 
discussed in the use case scenario in section 2.1, a clearly defined message structure and 
content representing data query criteria, data access requests and IRB review decisions 
need to be specified. Considering that FURTHeR is designed to connect to multiple data 
sources across institutions, IRB review from multiple institutions may be needed. In 
addition, since SUHD systems emerging at other institutions have similar access control 
needs, it is valuable to establish a shared view of the information exchanged between any 
SUHD system and any e-IRB system. 
However, SUHD systems are only one of the many types of CRI systems and there 
are potential benefits in integrating e-IRB systems with other CRI systems to streamline 
the clinical research process. For example, by integrating CTMSs with e-IRB systems, 
study protocol information can be shared and researchers do not need to enter duplicate 
information twice or many times when IRB applications to multiple sites are required. 
Any subsequent protocol change updated in the CTMS can be transmitted to e-IRB 







continuing review can also be automatically generated in CTMS by specifying 
corresponding parameters in the system. EDC systems, either implemented as part of 
CTMS or as a standalone system, by integrating with e-IRB systems, can ensure that no 
data can be collected in a study before IRB approval. Unanticipated adverse events can 
also be transmitted to the e-IRB systems from EDC or CTMS via a direct machine-to-
machine connection. For multisite studies, sometimes one IRB needs to rely on other 
IRBs’ review decisions. Integration between different e-IRB systems can enable 
application information and review decision sharing, thus making the communication 
more efficient between different IRBs and eliminating the needs for investigators to 
submit multiple applications for the same study protocol. Therefore, data sharing and 
exchange between e-IRB systems and other CRI systems can greatly streamline the 
clinical research process.  
Information models are the basis for retaining computable meaning by refining 
message structure and content when data are exchanged between heterogeneous computer 
systems. Without a standard information model for e-IRB systems, point-to-point system 
integrations will be needed that can cause a large amount of interface development. The 
model should be designed to represent information for the IRB domain in a higher level 
of abstraction in order to be generalizable across institutions and systems. This is 
considered a domain analysis model (DAM) in software engineering. With this IRB 
DAM: 
1. Existing e-IRB systems can use this model to develop a standard interface layer to 
achieve semantic interoperability with other CRI systems to streamline the clinical 







in participating institutions can facilitate joint review or federated review by relieving 
duplicative burdens on both IRBs and investigators.  
2. Structured information in e-IRB systems based on the model can enhance review 
quality and efficiency via automated review decision support enabled by utilizing the 
structured study protocol information and defined rules based on federal and local 
regulations. Computer-assisted review support is not intended to replace human 
review but to promote a partnership between human and computer-based resources 
and capabilities so the strengths of human beings and computers can be fully utilized. 
In addition, with structured IRB application information, it is easy to search across 
studies. An IRB considering a new protocol could search the application database and 
find similar studies and related ethical concerns and review decisions, which can be 
used as a reference for current review.  
3. A structured IRB application repository can become a valuable resource for various 
stakeholders in the research domain. This can make secondary use of human research 
metadata projects such as the Human Studies Database (HSDB) Project[46] much 
easier. It can also be useful for developing practical guidance for effective IRB 
oversight of human subject protection and developing an ongoing process to increase 
empirical knowledge about current “best practices.” 
4. New e-IRB systems can be developed using the IRB DAM as a reference model, thus 
avoiding the need to start from scratch. It will also enhance the compliance with 
federal regulations since the model covers major federal regulations. Even though an 







moment, the model can be used as a reference for designing application forms in 
word processing templates. 
2.3 Related Work 
To the best of our knowledge, there is no existing research on modeling the IRB 
oversight domain. However, there have been a number of efforts to model various aspects 
of biomedical research in general.  
2.3.1 CDISC Standards 
The Clinical Data Interchange Standards Consortium (CDISC) has developed a series 
of platform-independent standards to support the acquisition, exchange, submission, and 
archiving of clinical research data and metadata. The most relevant model from CDISC is 
the Protocol Representation Model (PRM), which is a representation of the elements of 
study protocol. It focuses on the characteristics of a study and the definition and 
association of activities within clinical trial protocols, including “arms” and “epochs.” It 
is designed to facilitate protocol information to be reused and repurposed across multiple 
documents, databases, and systems from study start-up through reporting and regulatory 
submissions.[47] 
2.3.2 BRIDG 
The Biomedical Research Integrated Domain Group (BRIDG) project developed a 
comprehensive domain analysis model for protocol driven research and its associated 
regulatory artifacts by coordinating the standards development efforts in HL7 Regulated 
Clinical Research Information Management (RCRIM), CDISC, and the National Cancer 







interoperability by standardizing and exchanging clinical trials data among different 
projects. BRIDG defined six subdomains: Adverse Event, Common, Protocol 
Representation, Regulatory, Statistical Analysis, and Study Conduct. It covers concept 
entities defined for planned, scheduled, and performed clinical trial activities. Certain 
subdomains in BRIDG such as Study Conduct, which includes the detailed scheduling 
and conduct of study activities are designed for CTMS systems and are not of interest to 
IRB. The Protocol Representation subdomain is developed based on PRM from CDICS, 
as mentioned above. It defines concepts and attributes associated with prospective 
clinical trials but lacks structural attributes related to retrospective studies, which 
compose a major category of human subject research. The Regulatory subdomain was 
originally designed for FDA regulated product submissions instead of IRB oversight. It is 
also too coarse-grained for computers to process by modeling the submissions at a 
document level.  
2.3.3 The Ontology of Clinical Research (OCRe) 
The Ontology of Clinical Research (OCRe) is a formal ontology for annotating 
human studies and supporting federated query on data and meta-data across various 
studies. Compared to BRIDG, which covers all phases of a clinical study, OCRe focuses 
on the design and analysis phase of studies. The study_protocol module in OCRe 
incorporates related classes from the BRIDG model. OCRe is designed as an OWL 
ontology that models the entities and relationships of human studies and it  has been used 
only for annotating existing study metadata (e.g., study design, eligibility criteria, 







studies. [46] OCRe is not designed for data sharing. However, it may later be used as a 
terminology binding for certain values sets in our IRB model. 
2.3.4 The Ontology for Biomedical Investigations (OBI) 
The OBI project is an international, collaborative effort to build an ontology to be 
used for annotation of Biomedical Investigations. The origin of OBI is in the molecular 
biology research domain.[49] Although it is aimed at developing cross disciplinary, 
integrated ontology including a set of broadly applicable terms for the detailed 
description of biological and clinical investigations, the current release still focuses 
mostly on terms describing biological experimental processes and their relevant 
components (e.g., Antigen binding, T cell activation, Immunization in vivo, etc.) It also 
lacks the definitions for the structure of a study protocol. Specifically, it defines the class 
protocol, which has only a subclass animal care protocol, which in turn has a subclass 
rodent care protocol. The protocol class has only two “has part” relations with objective 
specification and action specification, respectively.  
2.3.5 Biomedical Ethics Ontology 
Koepsell et al. proposed to develop an ontology for the biomedical ethics domain. 
Their paper described a vision of using the Biomedical Ethics Ontology (BMEO) to 
support automated informed consent document generation, sharing review opinions and 
decisions across ethics committees, automated review decision support, and reducing the 
vagueness in the review process by formalizing rules and regulations.[50] The ontology 
will include rigorous definitions of biomedical ethics terms such as autonomy, informed 







follow-up publication by DuBois questioned Koepsell’s paper by pointing out that 
ontology is ill-suited to describe regulatory definitions and ethical concepts that are not 
universal.[51]  
Although one of the goals of our project overlaps with the BMEO project (facilitating 
automated review decision support), I took a different approach and design principle. Our 
principle is to first capture all necessary information pertinent to a human subject 
research that is essential for IRBs to evaluate the study. Such information will be 
captured and represented in a structured way whenever possible, which is the foundation 
for later review decision support based on predefined rules or through binding to an 
ontology. I try to avoid modeling verbatim concepts defined in regulations unless they 
have a clear extension definition (e.g., vulnerable population is defined by federal 
regulations and OHRP guidelines via naming a list of vulnerable subject categories[52]). 
I do not model entities that do not require computer interpretation such as such as the 
standard language used in an informed consent, although it is possible to facilitate 
automatic informed consent generation in the future as a more advanced application of 
the model. Our goal is not to replace human review with a computer system, but to make 
the reviewer’s job easier by utilizing information collected in a machine-understandable 
way. In this way, I am trying to maximize the advantages of both human (IRB reviewers) 









ANALYSIS OF IRB APPLICATION SYSTEMS AT 
CTSA INSTITUTIONS 
The AAHRPP metrics on technology use of IRB application systems gave us a 
general idea about how applications are managed among U.S. IORGs. However, it is not 
clear what specific types of “online systems” exist. If we build a model, will our model 
be applied or useful to other institutions? To gain a deeper insight into the IRB 
application systems currently used in the U.S., I did an analysis of the IRB application 
systems currently used at CTSA institutions. 
The reason I chose CTSA institutions as the sampling target for the analysis is 1) 
CTSA institutions are leading academic medical centers and large healthcare delivery 
organizations in the U.S. and they are research intensive. A previous study shows that 
IRBs at large institutions have a heavier workload compared to small institutions;[13] 2) 
The CTSA program aims to build an environment to increase the efficiency and speed of 
clinical and translational research. CTSA institutions have a strong focus on adoption of 
CRI systems to achieve this goal. For example, according to the results from a 2010 
CTSA survey, 86% of CTSA institutions have an integrated data repository (IDR).[53]  
Many institutions are actively deploying electronic data capture tools such as REDCap or 









Therefore, the potential for system interaction between these CRI systems and e-IRBs 
can greatly benefit CTSA institutions by streamlining the research workflow and 
improving research efficiency.  
3.1 Analysis Methods  
All CTSA centers are listed at the CTSA consortium Web site 
(https://www.ctsacentral.org/institutions). I did the analysis by exploring the official IRB 
websites at each CTSA center and its participating institutions. Most IRB websites have a 
detailed IRB submission guideline or training documents or videos for investigators, from 
which I can directly tell what type of submission system is used and the system’s vendor 
if it is commercial software. For those institutions that do not have such information on 
their websites, I called or emailed the IRB office with the following questions: 
1. How does an investigator submit IRB applications? Hard copy, E-mail, portable 
device, or online?  
2. If an online submission system is used, is it developed in-house or purchased from a 
vendor? 
3. If it is a commercial software product, which vendor is it? 
If I called the IRB office more than three times and still could not reach the relevant 
personnel, then I counted it as unknown and excluded it from the final analysis. 
Compared to the regular survey or interview approach, our approach-- making full use of 
online resources-- avoided problems such as low response rate and long waiting periods 
that are common challenges faced by survey studies. At the same time, it gave us the 








3.2 Analysis Results 
All 61 CTSA centers were included in the analysis. Each CTSA center may have one 
or more partner institutions. For example, the University of Utah Center for Clinical and 
Translational Science (CCTS) has three participating institutions: University Health Care, 
Intermountain Health Care, and Veterans Administration Salt Lake City Health Care 
System (VA SLC).  Another CTSA center, the Harvard Clinical and Translational Science 
Center, is composed of 32 partner institutions. For those CTSA centers that have more 
than one partner institution, I chose two to three to analyze their IRB application systems. 
I ended up analyzing 121 individual institutions in the 61 CTSA centers. Among the 121 
individual institutions, there are 103 IORGs in total. This is because not every institution 
has their own IORG but some of them rely on an external IORG from a partner institution. 
For example, among the three partner institutions in the University of Utah CCTS, 
University of Utah and Intermountain Healthcare have their own IORGs, whereas VA 
SLC uses the University of Utah’s IORG. Usually one IORG uses a single submission 
method across different IRB panels but there are also exceptions. Among the 103 IORGs 
I analyzed, there is one IORG using two different submission systems for different IRB 
panels. Therefore 104 submission systems were analyzed in total. Eight of the 104 
systems were excluded because I could neither find relevant information on their website 
nor reach the relevant personnel by phone or email. The 96 systems are categorized into 
three top categories: Hard Copy, E-mail (Flash Drive or CD), and Online Submission as 
shown in Table 1. 
Online submission systems were further categorized into five subcategories:  







Table 1. Analysis Results of IRB Application Systems Used in CTSA Institutions 
System Type  Number of Systems  Percentage  
Hard Copy  10  10.4%  
E-mail (or Flash Drive, 
CD)  
17  17.7%  
Online  69  71.9%  
 Commercial e-IRB  31  32.3%  
In-House e-IRB  19  19.8%  
SaaS e-IRB  6  6.2%  
Community Source 
e-IRB  
3  3.1%  
 Not specified  10  10.4%  
Total  96  100%  
 
such e-IRBs are iRIS™ by iMedRIS™, Click IRB by Huron Consulting Group 
(originally Click Commerce), InfoEd by InfoEd Global, etc.  
2. In-House developed e-IRBs: e-IRB systems that were developed internally by the 
institution’s technology team. 
3. Software as a service (SaaS) e-IRBs: The e-IRB system and submitted IRB 
applications were hosted by a vendor and made available to customers as services. 
SaaS e-IRBs are accessed by users using a Web browser. Examples of SaaS e-IRBs 
are IRBNet, IRBManager, etc. 
4. Community source e-IRBs: A special type of open source software with institutional 







individuals.  Kuali Coeus[57] is an example of a community source e-IRB. 
5. Other online e-IRBs with unspecified system types. 
About 20% of IORGs use independent commercial IRB Services such as Western 
IRB and RCRC IRB as a complementary IRB review method for industry-sponsored 
clinical studies. 
3.3 Discussion 
From the analysis, I obtained a deeper insight into the IRB application systems used 
across the nation. Our major findings are listed below: 
1. As shown in Table 1, there are 71.9% IORGs using some type of online submission, 
which is higher than the AAHRPP metrics report sampled across the nation.  
2. Online submission is not equal to structured IRB application information. Some 
online submission systems simply allow investigators to upload the application 
document in Word or PDF format. Even for those systems that support Web forms, 
there is still a large proportion of free-text fields. Unstructured information is difficult 
to be processed by computers for further analysis or data sharing. 
3. The CTSA institutions prefer to purchase commercial software or develop their own 
e-IRB systems to SaaS e-IRBs, which are more suitable for small hospitals with 
limited resource. 
4. The design of each institution’s application templates or forms varies. Most 
commercial e-IRB systems such as iRIS™ and Click IRB support customizable form, 
which allows flexible localization. However, this also means that two institutions 







The varieties of IRB application forms will impede the interconnection between e-
IRB systems and other CRI tools. 
5. Many of the commercial e-IRB systems used by CTSA centers are part of the whole 
Electronic Research Administration (eRA) solution from vendors. A single vendor 
may provide a suite of software products for all kinds of research administration 
activities such as grant proposal preparation and submission, award management, 
publication management, etc. Besides the eRA solutions, some vendors also have 
software products for the actual conducting of a study, such as CTMS or EDC 
systems. Similar to the discussion about best-of-breed or single vendor Electronic 
Health Record (EHR) systems in the healthcare domain, there exists the same pattern 
in the clinical research domain—using a research package from a single vendor or 
using best-of-breed modules from multiple vendors. A single vendor solution has the 
advantage of better integration between different systems or modules, which provides 
a more streamlined workflow. However, a single vendor solution may not meet all the 
needs of an institution or the cost may be too high for a small institution. A detailed 
discussion about this issue is beyond the scope of this dissertation. The point is for the 
best-of-breed CRI solution, systems from different vendors or developed in-house 
need to be integrated to achieve a streamlined research workflow. Even for the single 
vendor solution, system integration is needed when multisite studies are conducted at 
multiple institutions. 
6. The IRB application systems used in one institution can be very diverse. One 
university can have multiple IORGs for different departments. Each of them may use 









Chapter 2 described the motivation of this dissertation project. The need for 
developing a standard information model for e-IRB systems in order to promote system 
interoperability in the clinical research domain was identified. In Chapter 3, the variations 
of IRB application systems were further analyzed. Considering a higher percentage of e-
IRB deployment and the support for customizable form design by some e-IRB systems, 
the potential for existing IRB application systems in large academic institutions to adopt 
a standard model was demonstrated. This chapter describes the method of the IRB 
domain analysis model development, which is primarily based on existing domain 
analysis and data modeling methodologies in software engineering and modeling efforts 
in the healthcare and research domain. The result of the IRB DAM includes the static 
(structural) entity-relationship model, the dynamic (behavioral) business process model, 
and the interaction model. A preliminary terminology binding effort to develop a domain 
vocabulary specification for data request related attributes is also presented in this chapter. 
4.1 History of Domain Analysis 
Before I describe the details of the IRB domain analysis model, I should define what 
a domain analysis model is. The term domain analysis was first introduced in software 







operations of a class of similar systems in a particular problem domain.”[58] In domain 
analysis, common characteristics from similar systems in an application domain are 
generalized. It is thus at a higher level of abstraction than system analysis, which focuses 
on a specific system. Since then, domain analysis (DA) attracted lots of attention and has 
been considered a key factor in successfully creating reusable components in software 
engineering by reuse of analysis and design information, in addition to programming 
language code.[59,60] 
A host of documented domain analysis methods are available in software engineering 
and there is no single standard domain analysis process defined. Ferre et al. evaluated the 
various DA methods and did a comparison of each method by the type of artifacts to be 
reused.[61] Different DA methods have different goals, and the DA process or 
representation for a domain analysis model varies according to the goals to be achieved. 
There is little agreement on the definition of the term domain analysis since the author’s 
definition is strongly influenced by the expected outcome of the DA process.  
On the other hand, some researchers may use a different term such as “Conceptual 
Modeling” to represent an abstraction modeling process similar to domain analysis.[62] 
Conceptual models are designed to describe the semantics of software applications at a 
high level of abstraction, which enables all stakeholders, including domain experts, 
analysts, and application programmers, to understand and communicate with each other 
successfully. 
HL7 defines a Domain Analysis Model (DAM) as “an abstract representation of a 
subject area of interest, complete enough to allow instantiation of all necessary concrete 







DAM includes both static (e.g.,  class and instance diagrams) and dynamic (e.g.,  activity 
and state diagrams) semantics of a domain. The HL7 Healthcare Development 
Framework (HDF) adapted a popular DA method in software engineering—Feature-
Oriented Domain Analysis (FODA)—to the healthcare business. FODA was developed 
by the Carnegie Mellon Software Engineering Institute (SEI) and focuses on the 
identification of distinctive features of software systems within a domain.[64] 
4.2 Domain Analysis Methodology for the IRB Model 
Domain analysis methods such as FODA in software engineering are mostly designed 
for software reuse. The conceptual modeling method presented by Embley et al. promotes 
that conceptual models can go beyond being mere blueprints; rather, they can constitute 
the basis for automatically or semiautomatically generating the software system itself. 
Although our IRB DAM has potential values in software reuse and model-driven 
software development, the major goal of the IRB DAM is to achieve interoperability 
among systems in the clinical research domain. Therefore, I adapted the FODA method 
and the conceptual modeling method in order to meet this requirement. Figure 2 
illustrates the overview of the IRB domain analysis process and the corresponding model 
artifact generated by each step. 
The first phase, context analysis, defines the scope of the modeling domain. In this 
phase, the relationships between the candidate domain and the elements external to the 
domain are analyzed.  The second phase, domain modeling, consists of entity-relationship 
modeling, which models the static (structural) semantics of the domain, and business 
process modeling, which models the dynamic (behavioral) semantics of the domain. The 








Figure 2. Overview of the IRB Domain Analysis Process 
 
model. It is independent of the underlying database design. Some literature refers to this 
as an information model or logical data model. In this dissertation, these terms will be 
used interchangeably. Terminology binding connects the entity-relationship model with 
domain vocabulary specifications to standardize the terminology that describes the 
domain. In this dissertation, only a preliminary terminology binding effort was conducted. 
A comprehensive domain vocabulary development is considered as a future development. 
The interaction architecture modeling phase specifies interactions and information 
exchange between an IRB system and other clinical research information systems to 
realize new features that are not supported by isolated systems. 
The entity-relationship model, the business process model, and the interaction model 
are formally represented using the Unified Modeling Language (UML). The following 







4.2.1 Context Analysis: Domain Scope 
The modeling scope of the IRB oversight domain is defined during the context 
analysis phase. Figure 3 illustrates the scope of the modeling domain and its relationships 
with its parent domain, subdomains, and peer domains. 
The IRB oversight domain is a subdomain of human subject research, which is a 
subdomain of the general biomedical research domain. During our analysis of CTSA IRB 
systems, I found that although federal regulations mandate only that IRBs review human 
subject research, it is not uncommon for IRBs to require investigators to submit an 
application for studies considered to be nonhuman subject research (e.g., studies using 
de-identified data for secondary analysis) and the IRB will make the final decision 
whether the study is nonhuman subject research. Our model does not reflect this type of 
study, since this is determined by institutional policy and it is considered to be an 
implementation-level issue. However, the model is extendable to support this type of 
study in an IRB system.  
Human subject research has several components throughout the life cycle of the study.  
IRB oversees only certain aspects that are closely related to protection of human subjects. 
There is significant overlap within the IRB and the study protocol domain. Study protocol 
is the blueprint of every human subject research project and it gives the IRB a 
comprehensive view of the study, including subject eligibility criteria and recruitment, 
planned study procedures and interactions, data management, and analysis plans, etc. It is 
essential for IRBs to evaluate the potential benefits and risks of a study. There are also 
certain aspects of a study that might not be covered in the study protocol but are 








Figure 3. Context Analysis for the IRB Oversight Domain 
 
subjects, vulnerable population participants, etc. 
IRBs are also responsible for monitoring the conduct of human subject research. 
Adverse event (AE) tracking is a subdomain of human subject research. However, not all 
AEs are reportable to IRB.  According to guidance from the Office for Human Research 
Protections, only unexpected AEs that are related or possibly related to participation in 
the research and cause a greater risk of harm than previously known should be reported to 
IRBs.[65] There are also other types of reportable unanticipated problems that are not 
AEs, such as a data breach or product (e.g., drug or medical device) problem. In addition, 










4.2.2 Domain Modeling 
The structural entity-relationship model is the core of the IRB DAM. It is used to 
acquire knowledge about the domain by modeling all physical and informational entities 
in the IRB oversight domain (e.g., study protocol, unanticipated problem, oversight 
committee, review record, etc.) and their relationships. It is the basis for supporting any 
internal or external automated tasks. The entity-relationship model is the most important 
artifact of the IRB DAM and will be described in detail.  
The behavioral business process model specifies the high-level features of an e-IRB 
system, with a focus on end-user perspective of the functionality of the application. 
Considering the potential variability in review workflows among different IRBs, the 
current business process modeling intentionally avoids detailed workflow design such as 
application review assignment, internal review processes, or meeting scheduling. System 
interactions with clinical researchers and IRB reviewers are modeled and considered to 
be applicable across institutions. The state transitions of an IRB application are also 
represented as part of the business process model.  
4.2.2.1 Modeling Tool 
The IRB DAM is represented in Unified Modeling Language (UML) and developed 
using Enterprise Architect (Version 9.2) from SPARX Systems. UML is a standard 
general-purpose modeling language that can be applied to all application domains (e.g.,  
health, finance, telecom, aerospace, etc.).[66,67] It was developed in an effort to 
consolidate the large number of object-oriented development methods in software 
engineering that had emerged and it is now maintained by the Object Management Group, 







engineering and system design. However, with the rich modeling capabilities of UML 2.x, 
UML has been commonly employed in modeling application domains in addition to 
specific systems. 
UML is a visual modeling language that can represent different perspectives of a 
system or a domain in diagrams. A diagram is the graphical presentation of a set of 
elements, most often rendered as a connected graph of vertices and arcs. There are many 
types of diagrams in UML and only a few of them were used for the IRB DAM. The 
UML Class Diagram is used to represent the entity-relationship model. The Business 
Process Model and Notation (BPMN) Process Diagram is used to represent the business 
process models. The UML State Machine Diagram is used to describe state transitions of 
an IRB application.  
4.2.2.2 Information Sources 
The FODA recommended several types of information sources to use while gathering 
information for domain analysis, including textbooks, standards, existing applications, 
and domain experts. Considering the special regulatory characteristic of the IRB domain, 
the content of the IRB model was driven by analysis of the following knowledge sources: 
4.2.2.2.1 AAHRPP Accreditation Standards 
The Association for the Accreditation of Human Research Protection Programs, Inc. 
(AAHRPP) is an independent, nonprofit organization that accredits high-quality human 
research protection programs in organizations in the United States as well as foreign 
organizations that are obligated to follow U.S. federal regulations.[68] The goal of the 







participants are respected and are protected from unnecessary harm. It has published a 
series of accreditation standards that are compliant with regulations from the U.S. federal 
agencies that oversee research with human participants such as the HHS and the FDA, as 
well as other departments or agencies that have additional requirements, such as the 
Department of Defense and the Department of Veteran Affairs. The accreditation 
standards also cite international ethical principles such as the Declaration of Helsinki 
from the World Medical Association (WMA) and the Good Clinical Practice Guideline 
(GCP) from the International Committee on Harmonisation (ICH).  
Specifically, the Evaluation Instrument for Accreditation (Version January, 2012),[69] 
and IRB Evaluation Checklist (Version December, 2010)[70] were used as guidelines in 
the IRB domain modeling process. The AAHRPP’s Evaluation Instrument for 
Accreditation defines three Domains of responsibility: Organization, IRB or Ethics 
Committee (EC), and Researchers. The IRB modeling used the “IRB or Ethics 
Committee” domain. Within each Domain is a list of Standards, and for each Standard 
there is a list of Elements that provide more specificity. A total of 5 Standards and 25 
Elements are defined in the “IRB or Ethics Committee” domain. The original Code of 
Federal Regulations (CFR) that are cited by each Element were reviewed for clarification 
or validation where needed. 
AAHRPP accreditation standards were used as a knowledge source because they 
incorporate major regulations and ethical principles on human subject protection, thus 
providing the domain analysis an easily accessible comprehensive knowledge source. The 
documents are well organized and written in an easy-to-understand language as an 







compared to directly using regulations as a knowledge source. In addition, more and 
more organizations are seeking AAHRPP accreditation for their human subject protection 
program. The IRB entity-relationship model can be used as a reference model for IRBs to 
design their application forms. Although this does not guarantee complete AAHRPP 
compliance, since AAHRPP also requires various operational procedures that are not 
reflected in the static IRB model, collecting necessary study information is the basis for 
developing standard operational procedures that are recommended by AAHRPP. 
4.2.2.2.2 Guidance Documents from OHRP and FDA 
The Office for Human Research Protections (OHRP) and the FDA both publish a 
variety of policy and regulatory guidance materials to assist the research community in 
conducting ethical research that is compliant with the HHS regulations.[71] These 
guidance documents address various topics in detail pertaining to human subject 
protection, such as the informed consent process, vulnerable population protection, 
investigational use of drugs and medical devices, etc. 
4.2.2.2.3 HIPAA Privacy Rule and Related Educational Materials 
The AAHRPP accreditation standards do not include regulatory items related to IRB 
from the HIPAA Privacy Rule. Educational materials provided at the NIH Web site were 
used for the domain modeling since they are easy to understand. Specific documents 
include “Clinical Research and the HIPAA Privacy Rule,”[72] “Institutional Review 
Boards and the HIPAA Privacy Rule,”[73] “Protecting Personal Health Information in 







Databases, and the HIPAA Privacy Rule.”[75] I referred to the original Privacy Rule 
whenever necessary. 
4.2.2.2.4. Existing Standard Models in the Biomedical Research Domain 
As discussed in the context analysis section, the IRB oversight domain is a sub-
domain of the human subject research domain, which is a subdomain of the general 
biomedical research domain. The existing standard models in the biomedical research 
domain from BRIDG and CDISC PRM overlap with the IRB model in certain areas, such 
as study protocols and adverse events. Since BRIDG already includes CDISC PRM, only 
the BRIDG model is used as a knowledge source for the IRB domain modeling. Model 
reuse has the following benefits: First, as domain experts have already devoted time to 
defining terms in these models I save myself substantial effort by not replicating that 
work. Second, by considering standard models during the model development phase, I 
made it easier to integrate the IRB model with the BRIDG model in future harmonization 
processes. Third, by reusing existing models that others already use, we improve the 
potential for future system interoperability. 
4.2.2.2.5 Domain Experts 
Two IRB domain experts were interviewed during the model development process. 
They both serve as IRB committee members at the University of Utah and have extensive 
experience in reviewing IRB applications. 
4.2.2.3 Domain Modeling Process 
The IRB entity-relationship model is the core of the IRB DAM. Figure 4 illustrates 








Figure 4. Overview of the Entity-Relationship Modeling Process 
 
a simplified procedure, which primarily involves iterations of process analysis, design, 
and review. 
First, all the key entities and their attributes in the IRB oversight domain were 
extracted from regulation-based guidelines including the AAHRPP accreditation 
standards, OHRP and FDA regulatory guidance documents, and HIPAA educational 
materials. For example, in the AAHRPP Evaluation Instrument document, Element II.2.D 
defines all the information elements that should be included in a status report for 
continuing review by a convened IRB. The model then defined the entity “StatusReport” 
with each information element as an attribute of this entity. 
Second, relevant entities and their attributes from the BRIDG model were reused 
especially when the regulation guidelines did not specify the necessary details of the 
domain. AAHRPP accreditation standards do not always list the specific information that 
should be reviewed by the IRB. For example, in the same Element II.2.D, AAHRPP only 
states a general operational requirement about the information that should be provided to 







For initial review of research by a convened IRB, policies and procedures indicate 
that when they are scheduled to attend an IRB or EC meeting, all members (including 
attending alternate members) are provided and review: The full protocol, application, 
or a protocol summary containing the relevant information to determine whether the 
proposed research fulfills the criteria for approval. 
 
AAHRPP does not define, or chooses not to define, what a “full protocol” or 
“protocol summary” includes. It is the IRB’s responsibility to define what is the “relevant 
information to determine whether the proposed research fulfills the criteria for approval.” 
In such cases, the study protocol related classes from BRIDG were reused. Since BRIDG 
focuses mainly on modeling clinical trials (either interventional or observational), it is 
missing the category of retrospective studies, which use existing health data for 
secondary analysis. As a result, some entities or attributes in the BRIDG model 
describing clinical trial protocols are not suitable for describing retrospective studies or 
social and behavioral science studies. For example, planned study subject experience or 
subject enrollment is not suitable for secondary analysis studies. Study arms and epochs 
are not applicable to survey studies. Therefore, when adapting the BRIDG model, the 
organization of some BRIDG classes was rearranged to properly describe all kinds of 
human subject research. 
Third, with a draft version of the IRB entity-relationship model developed from the 
first two steps, domain expert reviews were conducted to further refine the model. Not all 
entities or attributes about study protocol in the BRIDG model are interesting to IRB. 
Some of them might be important as a blueprint for study conduct or for meeting report 
requirements from sponsors, but they are not related to the IRB evaluation. Such 
information elements were eliminated in the IRB model through expert review and only 







time reviewing information that were not important to their decision making.  
Two IRB domain experts were interviewed for the model reviewing. Although 
domain analysis models such as BRIDG and the IRB DAM were designed to represent a 
higher abstraction of the domain and be understandable by domain experts, I still found 
the UML Class Diagram was not intuitive to all domain experts, especially for those 
without any modeling or informatics background. To make the model more 
understandable to domain experts, a concept map was derived from the IRB Class 
Diagram. Concept maps are graphical tools for organizing and representing knowledge. 
They include concepts, usually enclosed in circles or boxes, and relationships between 
concepts indicated by a connecting line linking two concepts.[76] Concept maps were 
originally developed as learning tools in cognitive psychology. However, they are now 
popularly used in knowledge representation and sharing. Compared to the UML Class 
Diagram, the concept map includes only the entities in the domain and their relationships 
without further details such as attributes or data types. The map shows the big picture of 
the IRB domain and looks much simpler than the UML Class Diagram. Concept maps 
can use colors to distinguish the central concepts from others, which makes the diagram 
more readable. One of the interviewed domain experts, with a background in informatics, 
directly reviewed the UML Class Diagram and the autogenerated documentation, which 
included a detailed description of each class, attributes, and relationships in the model. 
The other domain expert does not have an informatics background and was presented 
with the IRB domain concept map first, and then the UML Class Diagram and the 
autogenerated documentation.  







“yes” meaning “to include” or “no” meaning “not to include.” After the independent 
reviews were done by both domain experts, results were consolidated and conflicts were 
identified. A separate review session was conducted with both domain experts, in which 
consensus was achieved. The review results were incorporated with both the concept map 
and the UML Class Diagram.  
The final step was to map the information model to real-world IRB application 
systems to validate its comprehensiveness, which will be discussed in Chapter 5. 
4.2.3 Interaction Architecture Modeling 
The interaction architecture modeling phase for the IRB DAM differs from the 
architecture modeling introduced by the FODA method. The FODA architecture 
modeling focuses on architectural design within the domain application whereas the IRB 
architecture modeling focuses on architectural design of interactions between the domain 
application and external systems. This is determined by the different goals of the two 
domain analysis methods. Since the IRB DAM is mainly designed to achieve system 
interoperability, the interaction architecture modeling addressed this goal by describing 
interconnections and information exchange between e-IRB systems and other clinical 
research information systems. 
The interaction model, which is produced from the interaction architecture modeling 
phase, was represented using the BPMN Collaboration Diagram. BPMN is a standard 
Business Process Modeling Language (BPML) that is intended to provide a notation 
readily understandable by all stakeholders. It was developed by consolidating existing 
notations such as the UML Activity Diagram and Enterprise Distributed Object 







processes from different perspectives including the control flow perspective, the 
organizational perspective and the data perspective.[62,77] The BPMN Collaboration 
Diagram is one of the three submodels supported by BPMN and is the most suitable for 
describing the interactions between different systems (participants) using Pools and the 
message exchange between the participants using Message Flows. Therefore, BPMN 
Collaboration Diagram was chosen to model the interactions between e-IRB systems and 
other clinical research information systems. 
The interaction model was developed based on the analysis of current clinical 
research workflow and identification of potential system integration scenarios. It was not 
designed to cover all system interactions but illustrated only a few obvious ones for 
demonstration purposes. 
4.3 Modeling Results 
This section presents the domain modeling results, including the structural IRB 
entity-relationship model, the behavioral business process model, and the interaction 
model. A preliminary effort at building a domain vocabulary is also described.  
4.3.1 Concept Map 
Although the IRB concept map that was derived from the UML Class Diagram was 
originally used for facilitating domain expert reviews, it has the advantage of 
representing domain concepts and relationships in a more straightforward and simple 
manner. It is an even higher abstraction of the domain and it helps the business analyst to 
quickly grasp the key elements in a complicated domain from a modeling perspective 







during the modeling process and can be applied to other modeling efforts in the future. 
The concept map was developed using the CmapTools software (available for download 
at: http://cmap.ihmc.us). Each box in the diagram is a concept representing a physical or 
informational entity in the IRB oversight domain. The links between boxes represent the 
relationships between concepts. The concept map for the IRB oversight domain is 
comprised of 97 concepts and 132 relationships in total. As shown in Figure 5, it starts 
with the most general concept at the top of the diagram “Application,” which generalizes 
three types of applications: IRB applications, ancillary applications, and regulatory 
applications.  
Within the set of IRB applications are four types of applications: 1) Human subject 
research is the most common type of application reviewed by IRBs and the current IRB 
DAM focuses only on this type of application; 2) Research projects that do not involve 
human subjects are not mandated to be reviewed by the IRB according to federal 
regulations. However, some IRBs still require investigators to submit a nonhuman subject 
research application and the IRB will make the final decision; 3) Emergency use [78] 
defined by the FDA as the one-time use of an investigational drug or device for a single 
participant in a life threatening situation and is exempt from prior IRB review and 
approval, provided that the emergency use of a test article is reported to the IRB within 5 
working days of the date of the emergency use; 4) FDA regulations require local IRB 
approval before use of a Humanitarian Use Device (HUD), which is a device that is 
intended to benefit patients by treating or diagnosing a disease that affects fewer than 
4,000 individuals in the United States per year.[79] The emergency use of a test article 








Figure 5. Top-level Concepts Extracted from the IRB Concept Map 
our major goal of building the IRB DAM is to streamline the research workflow by 
promoting interoperability among clinical research information systems, the latter two 
types of applications are considered as future work. Nonhuman subject research 
applications are subject to local policy. Therefore, such details were not included in the 
core model; however, these three types of applications were defined in the concept level 
in the current IRB model and details can be modeled in the future. 
Ancillary applications are submitted to oversight committees other than IRB such as 
radiation safety review committees, scientific review committees, conflict of interest 
committees, data and safety monitoring committees, etc. Many IRBs require ancillary 
application approvals before providing the final IRB approval. These ancillary oversight 
committees may or may not require extra information besides the standard IRB 







many of them are required by local policies. The model, however, the model is designed 
to be able to support any extension by local IRBs.  
Regulatory applications are mandated by regulatory authorities such as the FDA. For 
studies involving investigational drugs or significant risk devices, regulatory applications 
such as investigational new drug (IND) or investigational device exemption (IDE) 
applications are required to be reviewed and approved by the FDA, in addition to the IRB 
approval. Although it is not the IRB’s responsibility to ensure appropriate regulatory 
approvals are obtained, many IRBs require investigators to submit the IND number or 
FDA support letter in the IRB application. Such requirements were also considered as 
local policies and not included in the core model. The model, however, is designed to 
support these requirements by defining constraining relationships between an IRB 
application and regulatory applications. 
The IRB concept map covers eight core areas (Figure 6), including Study Protocol 
core, Planned Study Administrative Activity core, Application Amendment and Renewal 
core, Application Status core, Unanticipated Problem Report core, PHI Authorization 
core, Ancillary Application Dependency core, and Regulatory Application Dependency 
core. The key concepts in each core are highlighted in green. 
The Study Protocol core represents the informational entities that pertain to the plan 
of a human subject research. It is essential for evaluation of the study’s benefits and risks. 
Example concepts in the Study Protocol core are planned study site, study subject 
selection, study conditions, financial sponsors, and planned study activities including any 
observational and interventional procedures. Many of the concepts in this area were 








Figure 6. An Overview of the Concept Map for the IRB Oversight Domain 
protocol typology specially designed for the IRB oversight domain. A classification of 
study protocols is needed because different study types need different informational 
elements to describe the study. For example, a retrospective study uses only existing 
health data and does not involve any physical contact with study subjects, which does not 
require screening or interventional procedure plans in the study protocol. In contrast, a 
prospective study protocol should describe in detail the recruitment process and all 
observational or interventional procedures that will be applied to study participants. A 
well-designed study protocol typology, with relevant information elements defined for 
each study type, can facilitate “smart” form design in e-IRB systems so that investigators 
do not need to answer inapplicable questions. It should also address the key points such 
as the level of risk considered by the IRB during the review process. 







clinical research domain to suit different purposes. For example, a common classification 
categorizes clinical research as experimental, quasi-experimental or nonexperimental 
(also referred to as observational research). Carini et al. developed the Study Design 
Typology as part of the Human Studies Database project[80] to standardize the 
classification of study designs in human research. It categorizes human studies into 
quantitative studies and qualitative studies with a focus on further classification of 
quantitative studies. This typology is designed to support the critical appraisal of 
evidence of human research and classification of new and ongoing research for scientific 
portfolio management and analysis. It is designed to distinguish only interpretive 
concerns among studies. There is no single classification schema that meets the needs of 
all scenarios. The existing study classification schemas are not best suitable for IRB 
review purposes. The IRBs’ goal is to protect human subjects in research, and the review 
process focuses on the evaluation of the risks to participants. Knowing if the study is 
quantitative or qualitative does not immediately help IRB understand the risks of the 
study since quantitative studies may be retrospective and only cause informational risks 
to study participants whereas qualitative studies may involve interviews with vulnerable 
populations that raise ethical concerns. Therefore, based on literature reviews and 
consulting with IRB domain experts, the IRB model developed a study protocol 
classification schema specifically for the IRB domain (Figure 7). Study protocols are 
categorized into retrospective study protocols and prospective study protocols depending 
on the time perspective of the study design. Prospective study protocols can be further 
categorized into experimental study protocols and prospective observational study 








Figure 7. The Study Protocol Typology for the IRB Oversight Domain 
associated with the study. Further detailed study design information for experimental or 
observational studies are specified by a coded attribute “design configuration,” the value 
set of which can be derived from Carini’s Study Design Typology. The informational 
elements describing each study protocol type including those from the Protocol 
Representation subdomain of the BRIDG model were rearranged so that the most general 
study protocol type only includes informational elements that are applicable to all types 
of studies and more specialized informational elements were defined for more specific 
types of study protocols. 
The Planned Administrative Study Activity core represents those activities that are 
not directly related to the analysis of study outcome such as participant recruitment 
procedures, compensation to study participants, and informed consent processes, etc. 
Strictly speaking, these activities are part of the planned study activities described in the 







concerns such as equitable subject selection and respect for person, IRBs always require 
investigators to specify the details of these activities, which may not be included in a 
typical study protocol, which focuses more on study outcome related activities. 
The PHI Authorization core covers the informational entities that are related to the 
IRB (or Privacy Board) as regulated by the HIPAA Privacy Rule. For example, the 
request for waiver or alteration of authorization describes the PHI data elements to access, 
as well as the justification of such access. Documentation of the IRB’s review and 
approval of the request is also required by the HIPAA Privacy Rule. In fact, what kind of 
PHI access has been approved by IRB is essential to achieve automated access control in 
SUHD systems and effective IRB oversight of PHI disclosure. The authorization 
document itself was not included in the core model since it does not require review and 
approval by the IRB, according to the HIPAA Privacy Rule.  
The Unanticipated Problem Report core defines the informational elements that 
should be reported to the IRB and corresponding action taken by the IRB. The 
unanticipated problem report is not only useful for protecting study subjects from 
avoidable harm during the study, but also helpful for the IRB to reevaluate the study 
during the continuing review process. This portion of the model adopted some concepts 
from the Adverse Event subdomain of the BRIDG model. Since adverse events are often 
required to be reported to other bodies such as a local Data and Safety Monitoring 
Committee, the sponsor or the FDA, a standardized format can facilitate automated report 
and avoid duplicate report preparation efforts. However, not all adverse events are 
reportable to the IRB. On the other hand, there are other types of unanticipated problems 







The Application Amendment and Renewal core defines information entities such as 
amendment items and status report that are related to the IRB’s continuing review. A 
standardized status report can be automatically generated from existing information 
stored in a CTMS by defining certain report parameters. 
The Application Status core represents information related to the status of an IRB 
application and can be shared with other clinical research information systems to 
automate a streamlined workflow. This can eliminate the needs for manually delivering 
paper-based IRB approval letters to different stakeholders in the research domain. 
The Ancillary Application core and the Regulatory Application core were already 
described as peer concepts of the IRB application in previous sections.  
4.3.2 UML Class Diagram 
The UML Class Diagram is the detailed entity-relationship model that describes not 
only the concepts and relationships, but also attributes and their data types in the IRB 
oversight domain. Each box in the Class Diagram is a class that corresponds to a concept 
with the same name in the concept map diagram. There are attributes listed in each box 
describing the properties of a concept. Each attribute is bound to a data type defined in 
the HL7 Version 3 Data Type Abstract Specification (Release 2).[81] Each data type 
defines the structural format of the data and influences the set of allowable values an 
attribute may assume. HL7 abstract data type was chosen because it was specifically 
developed for the healthcare domain and is independent from representational and 
operational concerns or specific implementation technologies, which makes it suitable for 
a domain analysis model. The complete model in UML diagrams can be accessed online 








Unlike the concept map diagram, which is color coded by the coordination of the 
concept in the IRB oversight domain, the UML class diagram is color-coded by the 
information sources that led to the creation of the class, as depicted in Figure 8. Classes 
that were adapted or adopted from the BRIDG model use their original color code and a 
bold red border was used to distinguish them from other classes. This will make the 
harmonization process with the BRIDG model easier in the future. Some classes that 
were adapted from the BRIDG model were also recommended in regulatory guidelines, 
but were color coded as BRIDG classes for the same reasons. The attributes of the 
AAHRPP recommended classes were either from the AAHRPP guidelines directly when 
available such as StatusReport or defined by referring to related OHRP or FDA 
guidelines or CFRs. The Miscellaneous class category includes classes that were created 
based on modeling best practices (e.g., parent and child classes in a generalization 
relationship) or based on domain expert review feedback. Table 2 provides a summary of 
the number of classes from each knowledge source. The knowledge sources were 
recorded in the “Note” field of the class (Figure 9). This information is used for future 
reference. For example, when the regulations or guidelines change, impacted classes can 
be easily identified and then updated. Most class and attribute names are self-explanatory 
and a brief definition for each class and attribute was documented in the “Note” field. 
4.3.2.2 A Glance at the IRB UML Class Diagram 
This section describes a few representative classes in the UML Class Diagram to 
explain the modeling techniques and demonstrate the modeling result. The complete 









Figure 8. Legend for the UML Class Diagram 
Table 2. Summarization of the Number of Classes by Knowledge Source 
 
 
Source Number of Classes Percentage 
Regulatory Guidelines 
(Mainly AAHRPP)  
30  30.9%  
HIPAA Privacy Rule  4  4.1% 
BRIDG Model  21 21.6%  
Miscellaneous  42 43.3%  








Figure 9. The Note Field of a Class Documenting the Knowledge Source 
Figure 10 provides a close look at part of the Class Diagram as an example. 
Highlighted with red circles, the diagram shows the class name on the top of each box. 
Each class has certain attributes listed under the class name. There are two parts 
composing an attribute: attribute name (e.g., applicationType) and attribute data type (e.g., 
CD). CD is the symbol for ConceptDescriptor defined in HL7 abstract data type 
specification. It refers to a concept defined in a value set. Compared to the string (ST) 
data type, which represents free text values, the CD data type allows only coded values 
that are machine-interpretable. There are arrows linking boxes, which represent the 
relationships between classes. For example, the generalization relationship (which 
sometimes is referred to as is-a relationship) is a relationship in which one class (the 
















representation of a generalization relationship is a hollow triangle shape on the parent 
class end of the line that connects it to one or more child classes. The child class 
IRBApplication inherits all the attributes defined in the parent class Application. Another 
type of relationship is the association relationship, which describes any type of 
association between two classes. In this example, Application is associated with 
Amendment. There is a third type of relationship called aggregation relationship, which 
shows a class as a part of another class. The UML graphical representation of an 
aggregation relationship is a hollow diamond shape on the whole class end of the line that 
connects it to one or more part classes. In the example, an aggregation relationship 
connects the whole class Amendment and the part class AmendmentItem meaning 
AmendmentItem is part of Amendment.  
A study protocol may change during the administration of the study. The BRIDG 
model defined the class StudyProtocolVersion to represent the content of a study protocol 
at a particular point in time. However, in the IRB oversight domain, not only the changes 
of the study protocol, but also why the changes were made and how these changes may 
impact the study participants, are important for IRBs in re-evaluating the study. Therefore, 
metadata about changes such as applicable study sites, impact, and reasons for change 
should be defined for each amendment item. An amendment item can be any previous 
submitted or newly added information with regard to the study protocol, informed 
consent and any other supporting material. The view of the study protocol at a particular 
point in time is considered to be an implementation level issue, which can be generated 
automatically based on merging the original study protocol and amendments. 







StudyProtocolVersion class, with IRB-irrelevant attributes removed and clinical trial only 
properties reattributed to children classes. For example, “accrualReportingMethodCode,” 
which is a coded value specifying the technique that is used for reporting study subject 
accrual data to the study sponsor is not relevant for IRB review. Therefore, it is not 
included in the IRB model. The “plannedStudySubjectExperience,” which is a 
description of what the study subject can expect to experience over the course of the 
study, applies only to prospective studies. Therefore, this attribute was moved from the 
StudyProtocol class to the ProspectiveStudyProtocol class. Some new classes and 
attributes related to study protocol that were not included in the BRIDG model but are 
important for IRB review were added to the IRB model (e.g., DataAccessRequest, 
VulnerablePopulation, etc.). A separate class StudySubjectsSelection was created to 
describe all study subject related attributes including inclusion criteria, exclusion criteria, 
target number, and supplementary details about vulnerable population (Figure 11). Even 
though the “inclusionCriteria” and “exclusionCriteria” attributes are defined as strings 
that are designed for human review, their values could be automatically derived from the 
structured EligibilityCriterion class especially for medical criteria. 
Structured or computable representation of eligibility criteria plays an important role 
in facilitating automated research participant screening, clinical evidence application, and 
clinical research knowledge management. There are a number of active research projects 
on this topic.[82–85] A deep analysis of computable eligibility criteria is beyond the 
scope of this dissertation. A simplified eligibility criteria expression model that combines 
clinical statements with logical connectors (e.g., and, or, not) was constructed in the IRB 















an overly sophisticated model. Any eligibility criterion that could not be expressed in the 
model, especially those nonmedical criteria such as “access to telephone,” can be stated 
in the free-text eligibility criteria attributes. 
There are also cases where the class definition in BRIDG is not quite clear or has a 
different perspective from the IRB’s interest. In these cases, the BRIDG class was 
renamed and redefined for the IRB domain. For example, BRIDG defined the class 
StudyLegalSponsor while IRB is specifically interested in the financial sponsor of a study. 
Although sometimes these two types of entities overlap with each other, the IRB model 
clarified this case by defining the class StudyFinancialSponsor. 
The BRIDG model used a naming convention for attributes with data type CD—all 
such attributes have a suffix “Code” (e.g., designConfigurationCode, phaseCode). 
However, although the HL7 data type CD represents any kind of concept that is usually 
defined in a code system, it is an abstract data type that is composed of multiple 
properties such as code, codeSystem, codeSystemName, codeSystemVersion, 
displayName, originalText, translation, and qualifier. Moreover, in cases of an exception 
value, the CD need not contain a code but only the original text describing that concept. 
Attributes named with a “Code” suffix may be confusing to domain experts since they 
might think it is simply a computer-interpretable code. Therefore, in the IRB domain 
model, the “Code” suffix was removed from attributes borrowed from the BRIDG model. 
As shown in Figure 11, the IRB model defines the data access request related classes 
for studies that require access to existing data for secondary analysis or participant 
recruitment. Neither the BRIDG model nor the AAHRPP guidelines cover this category 







DataElement and DataSource. DataElement describes the data categories to be requested 
(e.g., demographics, conditions, procedures, drug exposures, etc.) and specific data 
element names when necessary (e.g., gender, race, year of birth, month of birth, day of 
birth for the demographics category). DataSource describes where the requested data are 
from. This can be implemented in an e-IRB system by providing a list of data sources in 
an institution that are under the jurisdiction of the IORG. The attributes defined by the 
DataAccessRequest class are listed in Table 3.  
4.3.3 Concept Domain—Terminology Binding 
Our major goal in developing an IRB DAM is to achieve interoperability between e-
IRB systems and other CRI applications. The IEEE Glossary defines interoperability as 
“the ability of two or more systems or components to exchange information and to use 
the information that has been exchanged.”[86] Implementation of the IRB entity-
relationship model (information model) enables syntactic interoperability by specifying 
the structure of information being exchanged between different systems. However, to 
make the meaning of the content being exchanged understandable to the receiving system 
(semantic interoperability), an information model needs to be bound to value sets where 
each value set consists of one or more of the coded concepts. In HL7, the term “Concept 
Domain” is used to refer to “a named category of like concepts that will be bound to one 
or more coded elements.”[87] Every attribute with the HL7 data type CD in the IRB 
model should be bound to a Concept Domain, which is in turn bound to one or more 
value sets. Such value sets can be defined from scratch or by adopting existing 
terminologies or code systems if available. I defined the value sets for a few attributes in 









Table 3. Attributes Defined for the DataAccessRequest Class 
Attribute 
Name 
Definition Example Values 
dataAccessPur
poseCode 
the purpose of the data access 
request 




the identification level of the 
data requested (this can be 
derived from DataElement 
values) 









the time frame of the records 









Figure 12 shows an example value set defined for IRB application status and Figure 
13 shows an example value set defined for the vulnerable population category. However, 
a formal and comprehensive IRB domain vocabulary specification is considered as future 
work since it needs a significant amount of iterative development and evaluation effort. 
4.3.3.1 Research-Oriented Health Data Representation Model  
This dissertation is specifically focused on defining the values sets for data access 
request related attributes such as dataCategory and dataElementName because a 
prototype implementation of the IRB model as part of the dissertation involves 
transmitting this information between a SUHD system and an e-IRB system. In the last 
decade, various developments have occurred to specify clinical models (sometimes called 
templates or archetypes) to represent clinical data with structured data elements in the 
healthcare domain to address a multitude of purposes.[88] These models are developed 
mainly to address the storage and exchange of electronic patient records in healthcare 
settings. They are not suitable for representing data elements for secondary use of health 
data in the clinical research domain. In the IRB model, I adapted the Common Data 
Model (CDM) Version 4 from the Observational Medical Outcomes Partnership 
(OMOP).[89] The OMOP CDM is designed to support research by standardizing the 
structure and content of various health data sources. Although it was originally developed 
to support drug safety surveillance research, it has evolved to support clinical research in 
general. The entity-relationship diagram (ERD) of the OMOP CDM is represented in 
implementation levels for relational database table design. The OMOP ERD was 
translated to a high level domain information model (logical data model) represented as 









Figure 12. Example Value Set for IRBApplicationStatus 
 








added to the translated OMOP model based on domain expert consultation and this 
formed our Research-Oriented Health Data Representation (ROHDR) model. For 
example, the Observation class was extended to represent specific types of observation 
such as LabObservation, RadiologyObservation, PathologyObservation, PhysicianNote, 
Allergy Observation, Vitals, etc. A detailed documentation of the ROHDR can be 
accessed online at http://irb-dam.bmi.utah.edu. The DataAccessRequest.dataCategory 
attribute is bound to a value set consisting of all class names in the ROHDR model. The 
DataAccessReques.dataElementName attribute is bound to a value sets including the 
attributes defined for each data category 
4.3.4 The Business Process Model 
The behavioral aspect of the IRB DAM is the business process model represented 
using the BPMN Process Diagram and the UML State Machine Diagram. The current 
business process model focuses only on the high-level IRB review processes. Details 
about the IRB review workflow design are considered as implementation level issues. 
Figure 14 illustrates the initial IRB application and review process. Figure 15 illustrates 
the IRB continuing review process. Three roles (participants) are involved in both 
processes: investigator, e-IRB system, and the IRB reviewers. 
Besides the two business process diagrams, a state machine diagram was created to 
represent the status transition of an IRB application as shown in Figure 16. The “In 





























Figure 16. State Machine Diagram for IRB Application Status 
 
 







4.3.5 The Interaction Architecture Model 
The interaction architecture model is represented using a BPMN Collaboration 
Diagram. Figure 18 illustrates the interaction model for automated access control on 
secondary use of PHI as discussed in Chapter 2. Three roles (participants) are involved in 
the interaction: Investigator, an e-IRB system, and a SUHD system. Similarly, the 
interaction model for automated protocol extraction from a CTMS to an e-IRB system 
can be accessed online at http://irb-dam.bmi.utah.edu. Interaction models for integrating 
e-IRB systems with other CRI systems will be developed in the future as the adoption of 


















The structural IRB entity-relationship model was evaluated to validate its support for 
representing informational elements in an IRB application required at different 
institutions. The evaluation included comparisons with real-world IRB application 
systems from five representative institutions. These IRB application systems were chosen 
because they come from institutions across the nation and each of them is representative 
of a typical submission method or review model. Table 4 summarizes the five IRB 
application systems used in the evaluation phase. 
5.1 Evaluation Methods  
The evaluation was performed from January to March 2013. The most up-to-date 
Web forms or Word/PDF application templates during that period of time at each 
institution were used for the evaluation. Most institutions make their IRB application 
forms in Word/PDF format publicly accessible. For those institutions that need an 
account to access the application forms, I contacted the IRB office and a temporary 
access account was created for this evaluation project. For certain e-IRB systems that 
require institutional accounts, either an account was registered or equivalent Word/PDF 









Table 4. Summarization of the Five IRB Application Systems 
IRB System Name Institution System Type /Review Model 
ERICA University of Utah Customized commercial e-IRB 
/Institutional 
DISCOVR-E Vanderbilt  University In-house developed e-
IRB/Institutional 
Harvard IRB Harvard Medical School Word templates submitted via e-mail 
or hard copy (e-IRB  went live on 
March 18, 2013)/Institutional 
WIRBNET Western IRB Ad hoc e-IRB/Independent 
Commercial 
Central IRB (CIRB) National Cancer Institute Mixed submission method 











Word/PDF templates was extracted as an information item and mapped to the IRB entity-
relationship model (referred to as “Model”) with one of the eight mapping types as the 
mapping results (Table 5). 
5.2 Evaluation Results 
Table 6 summarizes the mapping results for the five IRB application systems. The 
detailed mapping results for each IRB are summarized and displayed using pie charts and 
are described in the sections below. The data were analyzed using IBM SPSS Statistic 20. 
5.2.1 University of Utah IRB 
The ERICA system used by the University of Utah IRB is an institutional e-IRB 
system and is accessible using a university issued ID. The fields from all Web forms 
including forms for the initial application, application amendment, application renewals, 
and unanticipated problem reports were mapped to the Model. There were a total of 280 
fields extracted from ERICA. In order to illustrate the mapping results more clearly, five 
categories of mapping--Exact Mapping, Equivalent Mapping, Partial Mapping, 
Supportable Mapping, and Derivable Mapping--are considered as certain forms of 
mapping and combined into a general category (Figure 19). The detailed distribution of 
each mapping category is illustrated in a separate chart as shown in Figure 20. The 
mapping results for other IRBs are illustrated in the same way. 
5.2.2 Vanderbilt University IRB 
The DISCOVR-E system used by the Vanderbilt IRB requires a Vanderbilt University 







Table 5. Description of the Mapping Types 
Mapping Type Definition Example 
Exact Mapping The form field can be exactly mapped 
to an attribute of a class in the Model. 
“Title of Study” StudyProtocol.studyTitle 
Equivalent 
Mapping 
The form field can be mapped to the 
Model by combining more than one 
attributes from one or more classes. 
“Describe all the procedures chronologically, from 
screening/enrollment through study closeout, which will be completed 
in the research project.” PlannedStudyActivity and all its attributes 
Partial Mapping The Model has a general attribute 
covering more than one related form 
fields but lacks the specificity defined 
in the form fields. 
“Request for waiver or alteration of informed consent 1) Purpose of 
the Waiver Request; 2) Explain why the research could not practicably 
be conducted without the waiver or alteration; 3) Explain why the 
research and privacy risk of the research are no more than minimal; 4) 
Describe the measures you will take to ensure the waiver or alteration 








Table 5 Continued 
 




The form field cannot be directly 
mapped to a class or attribute in the 
Model but it can be derived from other 
attribute(s).   
For status report, some IRBs ask “number of participants enrolled 
since last review” and “number of participants enrolled since the 
beginning of the study.” Only the first one is defined in the Model and 
the second can be derived by adding up the previous numbers.  
Supportable 
Mapping 
The form field is supported by 
defining value set(s) for a certain 
attribute in the Model. 
Some IRB asks for study personnel’s information such as contact 
person, internal staff, external sub-investigator, guest, etc. This type of 
information is supported by defining the value set for 
ResearchStaff.role by local IRBs. 
Out of scope The form field is defined according to 
local regulations or policies and it is 
intentionally excluded from the core  
Studies that involve only de-identified data or limited data set access 
are not required to be reviewed by IRBs by federal regulations. 








Table 5 Continued 
 
Mapping Type Definition Example 
 model. However, it is possible to 
extend the Model to support such local 
policies. 
for such studies and the IRB will determine if the study qualifies for  
nonhuman subject research 
Not Defined The Model does not have a 
corresponding class or attribute 
defined for the form field.  
Details about placebo-controlled studies, HIV antibody testing related 
details. 
Unclear The definition of the form field is not 
clear. 
“Number ineligible for study” about participant information in the 
continuing review form should be clarified, for example “Number of 
subjects ineligible after the screen procedure.” Some IRB asks very 
general questions like “How the rights and welfare of participants will 









































263 20.5% 23.6% 16.3% 10.6% 9.1% 13.7% 2.7% 3.4% 
Western 
IRB 
































confirmation that their application forms in Word format contain the same content as the 
Web forms in DISCOVR-E and are accessible to the public. The 18 total forms for 
mapping included initial and continuing review application forms for social and 
behavioral sciences and for health sciences and additional application forms for request 
for exemption and studies involving medical devices, specimens and data repositories, or 
vulnerable populations. Duplicate information items in different forms that can be 
eliminated using “smart” forms in an electronic system were included only once for the 
purpose of mapping. A total of 241 fields were extracted from the forms. The mapping 
results for Vanderbilt IRB are illustrated in Figure 21 and 22. 
5.2.3 Harvard University Faculty of Medicine IRB 
Twelve forms are included from the Committee on Human Studies (the IRB 
equivalent oversight body) at the Harvard University Faculty of Medicine. The term IRB 
is used for consistency throughout the dissertation. The following forms were included 
for mapping: the general form for initial application; extra forms for use of specimen or 
data; ionizing and nonionizing exposure; use of drugs, biologics, and devices; research 
involving minors; request for consent waiver form; exemption determination form; 
unanticipated problem report form; study renewal form; and study closure form. 
Duplicate fields across forms were included only once. The Harvard IRB switched from 
Word-based application forms to an e-IRB system in March, 2013.  
Because this dissertation research was already underway, it relies on the Word-based 




















































5.2.4 Western IRB 
Western IRB (WIRB) is an independent commercial organization providing IRB 
services for national and international studies. In our CTSA IRB analysis, I found some 
institutions required industry-sponsored studies to be reviewed by WIRB. WIRB supports 
both online applications using “smart” forms and E-mail or hard copy applications using 
the Word/PDF forms. The Word/PDF forms have the same content design as the Web 
forms. Seventeen forms were included in the mapping analysis, among them the initial 
application form, the investigator submission form for multicenter protocols, the initial 
review submission form for sponsors and contract research organizations (CROs), the 
initial review submission form for international sites, the screening procedures 
information form, the Humanitarian Use Device clinical on-label use form, the exemption 
determination form, forms for request for a partial and full waiver of authorization, the 
initial review submission form addendum for Department of Defense funded research, the 
unanticipated problem report form, recruitment bonus disclosure form, the study closure 
report form, the continuing review report forms, and forms defined for specific states 
according to local regulations. However, with the most forms and fields (304) defined 
among the five IRBs, WIRB does not define a standard study protocol form for the IRB 
application. Investigators and sponsors are required to attach a separate study protocol 
document along with the application forms. The mapping results for WIRB are shown in 
































5.2.5 National Cancer Institute’s Central IRB (CIRB) 
The NCI CIRB Initiative was designed to create a more effective and efficient clinical 
research effort by conducting full board review of multisite studies centrally, thus 
reducing the administrative burden on local IRBs and investigators.[90] The CIRB has a 
clearly defined scope of review, which includes only selected CTEP-sponsored (Cancer 
Therapy Evaluation Program) Cooperative Group trials. It does not review research 
involving prisoners, reports of emergency use of a test article, or requests for waivers of 
HIPAA authorization. The CIRB also reviews individual adverse event reports for studies 
without a Data and Safety Monitoring Board (DSMB) but it does not define a standard 
format for the report. Due to the limited scope of studies reviewed by CIRB, the number 
of fields defined in the CIRB application forms is less than in the application forms from 
other IRBs (141 fields in total).  
The CIRB is switching from its historic facilitated review model to an independent 
review model. In the independent model, the CIRB is the sole IRB of Record responsible 
for both study review as well as review of local context considerations for enrolled 
institutions. Therefore, the CIRB requires information describing local context 
considerations, which are identified and reported to the CIRB by the Signatory 
Institutions and Signatory Institutions Principal Investigators via annual and study-
specific worksheets.[91] 
Both study-specific application forms and annual report sheets defined by CIRB were 
included in the mapping analysis. A temporary access account was granted by the CIRB 
to access the online application documents. The mapping results are shown in Figure 27 

























Mapping the fields defined in the above five IRB application systems to the IRB 
entity-relationship model provides insight into the comprehensiveness of the model and 
the structure and varieties of real-world IRB application forms. The mapping results can 
direct future improvements to both model development and IRB application form 
design. However, since the evaluation was performed by myself, this is a limitation 
especially considering the complexity of the mapping categories. 
The proportion of Exact Mapping is relatively small for all five IRBs but there is 
great potential to increase it by proper redesign of the Equivalent, Supportable, and 
Derivable Mapping fields in the application forms. The mapping process and results 
also show that there is no direct association between electronic IRB and the proportion 
of Exact Mapping fields. Switching from Word/PDF application forms to e-IRB Web 
forms does not guarantee more structured application information. For example, WIRB 
accepts both online applications using its e-IRB system and PDF application forms sent 
either by mail or electronically. Both submission methods have basically the same 
content except that the e-IRB system has the “smart” form feature that guides users 
through the application process depending on users’ input. Equivalent Mappings 
represent the form fields that are currently in free-text format but can be potentially 
redesigned in a structured format as defined in the Model. Supportable Mappings are 
valuable sources for future development of the domain vocabulary for the Model since 
many Supportable Mapping fields suggest the possible values for a certain attribute in 
the Model. For example, according to the list of options defined in the application 




enrollment to date,” “enrollment in progress,” “no longer enrolling, but active 
intervention,” “no longer enrolling, completed intervention, long-term follow-up,” 
“enrollment permanently closed, only data analysis,” “study closed,” etc. Derivable 
Mappings reflect form fields that can be removed to eliminate duplicate manual entries 
by investigators when they can be automatically populated by the system based on other 
information items. An example of this is that some IRBs ask specifically about the age 
of participant, which can be automatically derived from structured eligibility criteria.  
In contrast, most Partial Mappings reflect the limitations of using a structured model 
to cover all information entities in the IRB oversight domain. Partial Mappings 
represent the form fields that are specified in finer granularity in the real-world IRB 
application systems but defined using one general attribute in the Model. In most cases, 
these are the free-text justifications or explanations of different aspects of a single 
ethical concern (e.g., request for waiver of HIPAA authorization, plan for minimizing 
the study risks, etc.). These aspects cannot be defined in a structured way in the Model 
and there is no need to do so since this information is solely for human understanding. 
Examples of Partial Mappings from WIRB include detailed information items 
concerning screening procedures (e.g., will a call center be used; how is information 
stored at the call center; if it is stored in a database, describe the security measures; if it 
is stored on paper, how and where will the paper be stored and who has access to the 
paper). All these fields are mapped to PlannedStudyActivity.activityDescription when 
the value for PlannedStudyActivity.reason is “screen” in the Model.  
The Out-of-scope Mapping fields usually represent specific local context 




individual institutions can decide to include them as local extensions. For example, 
some IRBs require certain confirmation fields to be checked by investigators that are 
designed for educational purposes. Specifically, some IRBs ask the investigator who 
intends to enroll pregnant women to confirm that 1) No inducements will be offered to 
terminate a pregnancy. 2) Research teams will have no part in decisions related to the 
timing, method, or procedures used to terminate the pregnancy 3) Research teams will 
have no part in determining the viability of a neonate. Such information can be 
designed as check box fields in the application form, included as instructional or 
educational information in free-text format, or provided in separate training materials. 
Among the five IRB application systems, WIRB and CIRB have the most Out-of-scope 
Mappings because of their different review models. The application forms from these 
two institutions are designed to consider various local contexts and regulations related 
to human subject research, which are usually not required explicitly by local IRBs. For 
example, WIRB requires applicants to attach the clinical trial budget for Canadian sites 
according to the Canadian Tri-Council Policy Statement. Similarly, WIRB defines 
information items for New Jersey studies involving inclusion of decisionally impaired 
subjects because New Jersey Statute 26:14-5 requires investigators to provide additional 
protections for subjects who are unable to consent for themselves. In addition, WIRB 
provides informed consent form development and translation services that are not 
typical among regular IRBs. Form fields like these were considered as out-of-scope for 
the Model.  
However, in other cases, some common local considerations may be appropriate to 




submit an application even though a study is considered nonhuman subject research by 
the investigator. Currently the Model does not address the details of this type of study 
but should be extended as future work.  
The Not-Defined form fields reflect elements that are not covered by the current 
knowledge sources used for developing the Model but are worth considering due to the 
important role they play in human subject protection. During the mapping analysis, 
several areas such as humanitarian use device and use of radioactive drugs were 
identified that are regulated in federal laws but that are not included in AAHRPP 
guidelines. Section 801 of the Food and Drug Administration Amendments Act (also 
known as FDAAA 801) requires “applicable clinical trials” to be registered with 
ClinicalTrials.gov. Although it is not the IRB’s responsibility to monitor proper 
registration of regulated studies, Federal Regulation 21 CFR 50.25(c) has special 
requirements with regard to the informed consent document for this type of research 
that should be reviewed carefully by IRB. Therefore, corresponding classes and 
attributes in these areas were added to the Model after the mapping analysis. There are 
also undefined form fields in the Model that are based on best practices. For example, 
some IRBs ask for extra details for placebo-controlled studies. Federal regulations do 
not address this specific type of study but some IRBs require more information due to 
potential risks posed by this type of study. A collection of such specializations is 
valuable to form best practices in the IRB domain and should be discussed in future 
iterative development of the Model. 
The Unclear forms fields should move IRBs to more clearly define fields in their 




defined in an investigational drug data form may cause confusion to researchers. Overly 
general questions such as “how the risk of the study will be minimized?” or  









This chapter describes a prototype implementation for integrating a SUHD system 
with an e-IRB system to achieve automated access control on PHI data use for research 
purposes as proposed in Chapter 2. 
6.1 System Overview 
The SUHD system chosen is the FURTHeR project as described in Chapter 2. It 
provides a Web-based data query and export interface (referred to as FURTHeR data 
access interface or FDAI hereafter) for investigators to directly access aggregated or 
individual-level health information. The FDAI is adapted from the i2b2 Web front end. 
The e-IRB system chosen is ERICA, which is the electronic IRB application and review 
system used at University of Utah. ERICA is commercial software with customized 
application forms designed by the University of Utah IRB.  
The FDAI and ERICA are built on different software platforms, which is not 
uncommon in an enterprise. The FDAI is an HTML and JavaScript Web application with 
PhP support, connecting to the Java-based federated query engine at the backend. ERICA 
is a Web-based portal built on the .NET framework. It also has an add-on module called 
Click Commerce Extranet that provides a set of Web services enabling external 







To integrate these two systems, the Web services technology is a perfect solution since 
Web services provide a standard means of interoperation between different software 
applications running on a variety of platforms.[92] 
6.2 Interface Specification Design 
The first step was to develop an interface specification, which defined all functional 
requirements to realize the use case scenario illustrated in Figure 20. The IRB entity-
relationship model was used as a reference model when developing the input and output 
parameters of each service interface. The interface specification was reviewed by the 
ERICA development team. A few rounds of revisions were made based on feedback from 
this team to accommodate the system’s local configurations and limitations. The 
complete interface specification is listed in Table 7. 
The “original query ID” referred to in the service interfaces is the identifier 
automatically generated by the FURTHeR data access interface for each user-constructed 
query. In this prototype implementation, the original FURTHeR query ID is sent to 
ERICA in addition to the actual query (eligibility criteria) message in XML format. This 
implementation strategy makes later data export service much easier since it only needs 
to refer to a simple ID to retrieve the query instead of parsing the whole XML query 
message. The original query ID and the XML query message were designed as hidden 
fields in ERICA so that they are not visible to end users, which makes the user interface 
cleaner. Human-friendly inclusion and exclusion criteria are automatically translated 
from the XML query message and sent to ERICA, but they were designed as non 















Retrieve a list of all IRB 
applications submitted or 
participated in by a specific user 
User ID A list of IRB applications, each of 
which contains study summarization 
information (e.g., study title, PI, 
original query ID, data access 
request, application status, etc.) 
createIRBAppl
ication 
Initiate a new IRB application 
from the FURTHeR health data 
access interface  
PI ID, original query ID, structured 
eligibility criteria, free-text inclusion 
criteria and exclusion criteria, data 
sources, number of records, data 
element request 












Description Request Parameter Response Result 
updateIRBApp
lication 
Update an existing IRB 
application from the FURTHeR 
health data access interface 
IRB application ID, original query ID, 
structured eligibility criteria, free-text 
inclusion criteria, exclusion criteria, data 
sources, number of records, data element 
request 







that was created from the FDAI, they need to update the application using the FDAI. This 
ensures that the free-text eligibility criteria are always consistent with the original query 
ID and the corresponding XML query. It can also eliminate the need to build a 
sophisticated user interface for structured eligibility criteria definition in ERICA, which 
is not currently supported. A similar strategy was employed for the data element request 
field, which specifies the data categories and specific data elements to export from 
FURTHeR. The structured data element request is represented using JSON (JavaScript 
Object Notation), which is often used as a simplified alternative to XML. 
6.3 Implementation and Workflow Demonstration 
After achieving consensus on a clearly defined interface specification, the ERICA 
development team configured the Web services layer to support the functions defined in 
the interface specification. On the FDAI side, the e-IRB integration was implemented as 
an i2b2 Web client plug-in. The e-IRB integration plug-in invokes the Web services from 
ERICA, collects required user input, and implements certain local functions such as 
query and data request translation, user action auditing, and access control for data export. 
The following screenshots illustrate the work flow of the integrated system. 
1. The investigator logs into the FURTHeR data access interface, composes a data query, 
specifies the data sources, and runs the aggregated count query (Figure 29).  
2. If the investigator is satisfied with the returned count for the study cohort, he or she 
then may require access to row-level identifiable data for further analysis, which 














approval for the row-level data. (The query for aggregate data is considered 
nonhuman subjects research and does not require IRB approval.) 
3. The investigator initiates an IRB application directly from the FDAI using the 
previous query as inclusion and exclusion criteria and then clicks the “Initiate IRB 
Application” tab of the e-IRB integration plug-in. The investigator is required to 
enter some basic study information, drags and drops the previous query, and 
specifies the data categories (e.g., Demographics, Procedures, Conditions, etc.) and 
the data elements under each category (e.g., date of birth, race for demographics) he 
or she wants to access. The data categories and data element names are from the 
ROHDR model (Figure 30). 
4. After filling in the form, the investigator clicks the button “Initiate an IRB 
application” and all the study related information is sent to ERICA via a Web 
service, and the newly created IRB application ID is returned. The query composed 
at the data access interface is represented in XML format (Figure 31), which is 
unlikely to be comprehensible to IRB reviewers. A program was developed to 
translate the XML query into a human understandable format represented by 
inclusion and exclusion criteria (Figure 32). A similar strategy applies to the data 
element request that uses JSON as the machine interpretable format. 
5. The investigator clicks the ERICA link and is directed to the ERICA Web portal to 
finish the rest of the application, with data request related fields collected from 
FURTHeR automatically populated. (Note: Single Sign-On is not supported in 
ERICA now but it can be easily configured in the future so the user will be directly 






























































6. The investigator can obtain a quick view of the submitted IRB applications via the 
e-IRB integration plug-in. He or she can also modify the query and data element 
request that were submitted with an IRB application. If the IRB application is 
approved, the data export function will be enabled. The investigator may click on 
the “Export the data” link in an IRB application status page (Figure 33) to run the 
approved query and obtain the data. Since the IRB application is stored with the 
original query ID and structured data element request, FURTHeR query engine can 
easily interpret such information to return the data set approved by IRB, thus 
realizing automated access control based on IRB approval. 
7. A log table is created in the FURTHeR end to store user-initiated actions related to 
data export for future analysis or audit (Figure 34). 
6.4. Summary of the Prototype Implementation 
Currently the FURTHeR query engine does not yet support PHI query and 
federation. This prototype implementation demonstrates the feasibility from the 
workflow perspective in the front end. The development work was performed on test 
instances of the data access interface and the ERICA system to avoid interrupting the 
production users. 
The front-end implementation using an i2b2 plug-in can be easily adapted by other 
institutions that already deployed the i2b2 suite as their data management solution. 
According to the i2b2 Website, there are over 50 institution users of the i2b2, including 
over half of the CTSAs.[93] This means that our IRB-based access control can be 



















DISCUSSION AND CONCLUSION 
7.1 Summary 
This dissertation analyzed the problems associated with information technology use 
in the IRB oversight (ethics review) domain. Over 100 IRB application systems used at 
CTSA institutions were analyzed with regard to their submission method (e.g., paper, e-
mail, or online) and the sources of online systems (e.g., vendor, in-house built, SaaS, 
community source, etc). The lack of standardized IRB application forms caused 
inefficient and inconsistent review and cumbersome workflow due to disconnect between 
systems. The need for building a domain analysis model for IRB oversight was also 
discussed. The goal of developing an IRB domain analysis model is to standardize the 
structure and content of IRB application forms and promote system interoperability 
among CRI systems to streamline the clinical research process. 
This dissertation contains a comprehensive literature review on existing domain 
analysis models and ontologies that are related to the IRB oversight domain. Although 
some of the existing models or ontologies overlap with the IRB domain to a certain 
extent, no previous research specifically addressed the modeling issue in this domain. A 
domain analysis process was designed in this dissertation to address the major goal of 
building an IRB DAM based on several domain analysis methods from software 






understanding UML diagrams, which was also encountered in this project. Concept map 
technology was used for domain expert understanding and review of the model, which is 
a lesson learned during the modeling process and can be applied to other modeling 
research projects. The final IRB DAM includes the structural entity-relationship model 
and the behavioral business process model, as well as the interaction architecture model. 
The IRB entity-relationship model (information model) is the most important component 
of the entire IRB DAM and was evaluated by a comparison with five real-world IRB 
application systems. The evaluation results were discussed in detail. A prototype 
implementation of the model integrated the FURTHeR data access interface with the e-
IRB system ERICA in a testing environment. It demonstrated automated access control 
on PHI based on IRB approval. 
Development of the IRB DAM was initially motivated by addressing the need to 
integrate a health data query system and an e-IRB system to realize automated access 
control on PHI based on IRB approval. However, the value of the IRB DAM extends 
beyond this use case. Structured and computable IRB application information can 
facilitate automated review decision support with predefined rules, thus enhancing the 
review quality and efficiency.  More importantly, the IRB DAM can be used as the basis 
for data exchange message development between e-IRB systems and various CRI 
systems. Effective exchange and sharing of study data and metadata among various CRI 
systems is the key to streamline the clinical research process. A weak link in the chain at 
any point can cause unnecessary waste of resources and time. Development of the IRB 
DAM fills a gap in standardization and modeling efforts in the IRB oversight domain in 







The model validation process revealed limitations of the IRB DAM in representing 
certain aspects of real-world IRB applications, especially in defining information 
elements about subjective evaluations and justifications from investigators for a certain 
study activity, or foreseen events that can be fully expressed only with free text. This 
limitation is caused by the nature of information models whose strength lies in 
representing discrete and machine-understandable data elements, but not free-text 
information. Electronic IRB systems designed with structured application forms and 
predefined review rules cannot replace human review. The goal of building the IRB 
DAM is to promote standardization in IRB application forms that can enhance more 
efficient and consistent ethics review across IRBs and improve system integration to 
streamline the clinical research workflow. 
I performed the evaluation of the model myself, which may cause some mapping 
biases. However, the actual value of the evaluation does not lie in the specific numbers 
listed in the mapping result table (Table 6). As demonstrated by the complicated mapping 
results, the purpose of the evaluation is not to categorize the model simply as “good” or 
“bad.” There is no gold standard regarding to the design of IRB application forms. The 5 
IRB application systems chosen in the evaluation phase are representative across the 
nation, but this does not mean their application forms are perfect. The comparison 
between the IRB model and the real-world IRB application forms identified 1) if the 
model has covered the core information elements required by IRBs; 2) for information 
that are not covered in the model, what belong to local context and should not be 






of the model according to best practice; 3) what information that are currently free texts 
can be defined in a structured format according to the model; 4) what fields in the current 
IRB application forms should be clarified. In short, the evaluation provided insight with 
regard to future improvement to both the IRB model development and real-world IRB 
application form design. 
This dissertation only did a prototype implementation of the model in a testing 
environment. Although the demonstrated integration of ERICA and FURTHeR showed a 
streamlined workflow for PHI data access, a formal evaluation of performance 
improvement and user satisfaction of the integrated workflow is needed to make the 
proposed solution more convincing. However, implementing the integration between the 
two systems in the production environment will involve complicated administrative 
procedure change and political discussions, which is considered as future work.    
7.3 Future Direction 
Like any modeling effort, development of an IRB DAM that meets real-world 
application requirements needs many rounds of iteration and revision. As future work, we 
envisage continuing iterative development of the model by collaborating with more IRB 
domain experts and clinical researchers. A formal evaluation of the expressiveness of the 
data request related classes needs to be performed, possibly by annotating previously 
submitted IRB applications.  
We plan to promote the adoption of the IRB model by collaborating with other CTSA 
centers that have e-IRB implementations according to the analysis result in Chapter 3. 
Although the e-IRB system in our prototype implementation was integrated with a SUHD 






and EDC systems, which will be part of the future work to demonstrate the 
implementation of the IRB model. At the same time, we plan to integrate the IRB DAM 
with the BRIDG model through a harmonization process developed by BRIDG. BRIDG 
is a well-known modeling effort that has a great impact in the clinical research domain 
across the nation. Integrating our model with BRIDG will complement the regulatory 
artifacts in BRIDG and raise the awareness of our model among other institutions.   
A comprehensive domain vocabulary specification for the IRB DAM needs to be 
developed to achieve semantic interoperability. This can be achieved by combining the 
validation results from Chapter 5 (especially those Supportable Mapping fields), domain 
expert interviews, and existing terminologies in the healthcare and clinical research 
domain. In addition, computable review rules can be developed based on the structured 
information model and applied to e-IRB systems to facilitate ethics review decision 
support. More advanced features such as computer-assisted consent form generation 
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